(NASDAQ:NDRM) shares saw light trading volume with 0 shares changing hands in the last trading session. Volume was down 100.00% under the stocks average daily volume.
Traders are a little more bullish on NeuroDerm Ltd. – Ordinary Share if you take into consideration the decrease in short interest. The company recorded a fall in short interest of -11.73% as of October 13, 2017 from the last reporting period. Short shares fell from 1,302,514 to 1,149,750 over that timeframe. With short interest at 1,149,750 and short average daily volume at 340,525, the short-interest ratio is 3.0 and the short interest percentage is 0.04% as of October 13.
The following firms have recently changed their position in NDRM. Rock Springs Capital Management Lp bolstered its holdings by buying 153,621 shares an increase of 182.7% in the quarter. Rock Springs Capital Management Lp now controls 237,700 shares with a value of $7,107,000. The value of the position overall is up by 218.4%. Rhenman & Partners Asset Management Ab expanded its investment by buying 319,108 shares an increase of 223.9% as of 06/30/2017. Rhenman & Partners Asset Management Ab currently owns 461,654 shares valued at $13,803,000. The total value of its holdings increased 336.1%.
As of the end of the quarter Gw&k Investment Management, LLC had sold 680 shares trimming its position 0.7%. The value of the investment in NeuroDerm Ltd. – Ordinary Share increased from $2,924,000 to $3,778,000 increasing 29.2% quarter to quarter. Cutler Group LP added to its ownership by buying 1,900 shares an increase of 1,900.0% from 06/30/2017 to 09/30/2017. Cutler Group LP owns 2,000 shares worth $0. The value of the position overall is down by 100.0%.
On July 21 analysts at Deutsche Bank released its first research report on the stock setting a rating of “Buy”. On August 2 the stock rating was downgraded from “Buy” to “Neutral” by analysts at Roth Capital.
The company is now unchanged by 0.00% since yesterday’s close of $38.85. Shares last traded at $38.85 just a bit higher than the 50 day moving average of $38.84 and which is quite a bit above the 200 day moving average of $32.05. The 50 day moving average was up $0.01 or +0.02% and the 200 day average went up $6.80 or +21.21%.
In the latest earnings report the EPS was $-1.98 and is estimated to be $-2.20 for the current year with 26,345,000 shares outstanding. Next quarter’s EPS is forecasted at $-0.58 and the next full year EPS is anticipated to be $-1.95.
NeuroDerm Ltd., launched on March 18, 2003, is a clinical-stage pharmaceutical company. The Company is involved in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Business’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701..